Millennium Pharmaceuticals Inc. (MLNM)

All Comments on MLNM

  • commenter
    madiasha
    Apr 13 03:35 PM
    Millennium Has Nothing to Fear from a Takeda Takeover [view article]
    Bad for stockholders. Cash deal creates tax impact while a stock swap would give a choice. Also, I think the pipeline is worth much more. Velcade alone might well be one of the greatest blockbusters of history. I think this is deal suspect. Reply
  • commenter
    Daniel
    Jacome
    Apr 13 03:06 PM
    My Website
    Millennium Has Nothing to Fear from a Takeda Takeover [view article]
    MGI Pharma, then PHRM, then MLNM -- BMRN is next, we think. Also hearing BIIB is still trying to get something done by year end.

     Reply
  • commenter
    Roger G
    McCorkle
    Apr 10 02:21 PM
    My Website
    Wall Street Breakfast: Must-Know News [view article]
    Re: GregoryY


    Considering that Soros makes more money in the markets in a week than Greenspan has in a lifetime, I think I know who opinion I value     Reply
  • commenter
    GregY
    Apr 10 11:57 AM
    My Website
    Wall Street Breakfast: Must-Know News [view article]
    Soros vs Greenspan. This is an ideologically colored debate in an economic arena - Social Liberal Democrat, who believes the Government, can do ANYTHING vs Objectivist Libertarian. As long as one remembers that these are believes and opinions, rather than superior knowledge, we can pace our bets and enjoy the entertainment. Reply
  • commenter
    Moyshe
    Apr 10 09:09 AM
    Wall Street Breakfast: Must-Know News [view article]
    Hi dear Eli , I really enjoy your post thank you very much ,

    I am asking you also please , if you can to be in contact with me ,

    moshegothelf@gmail.com

    Thank you ,

    Kol Tuv

    Moshe     Reply
  • commenter
    Nigelnyc
    Apr 10 08:57 AM
    My Website
    Wall Street Breakfast: Must-Know News [view article]
    Finally the wall street breakfast comes out early enough where I can read it! Congratulations! Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:17 AM
    My Website
    General Discussion on MLNM
    Is this a buy or a sell? Reply
  • commenter
    bsrichard
    Mar 06 03:32 PM
    Cancer Stocks Hammered Once Again [view article]
    Alan,

    What are your thoughts on Chemokine Therapeutics Corp (CHKT)?

    And Meridian Co LTD (MRDAF)?
    Reply
  • commenter
    bsrichard
    Mar 06 11:48 AM
    Cancer Stocks Hammered Once Again [view article]
    please ignore the comment above. it was posted in the wrong thread.
    Reply
  • commenter
    bsrichard
    Mar 06 11:47 AM
    Cancer Stocks Hammered Once Again [view article]
    Maybe BofA should by this one too.

    Which bank took the highly rated debt at a discount from TMA?     Reply
  • commenter
    Alan
    Brochstein
    Mar 05 07:06 PM
    My Website
    Cancer Stocks Hammered Once Again [view article]
    I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot. Reply
  • commenter
    bsrichard
    Mar 05 12:23 PM
    Cancer Stocks Hammered Once Again [view article]
    Hi Alan,
    What is your current opinion on Clarient (CLRT)?
    Thanks very much,
    Don     Reply
  • commenter
    tech man
    Nov 27 08:27 AM
    My Website
    Russell 1,000's Best, Worst Performers Since the 10/9 Top [view article]
    good up to date articles. Reply
  • commenter
    Alan
    Brochstein
    Jun 26 03:03 PM
    My Website
    Cancer Stocks Hammered Once Again [view article]
    Thanks for the comment and the compliment. Thanks also for the information. Contact me by phone or email if you would like to discuss your ideas. Reply
  • commenter
    hpski
    Jun 26 12:45 PM
    Cancer Stocks Hammered Once Again [view article]
    Great post! It would be quite useful if your excel file could be downloaded, then someone could sort on other attributes, or even add some, e.g. #drugs in phase 3, total #drugs in pipeline, #big pharma collaborations, PADUFA dates, if any, etc. I'm offering a few comments vis-à-vis individual companies: I think EXEL, which probably has the deepest pipeline on your list, is gaining because investors believe Glaxo will take XL647. I believe it's, "show's over", for TELK (Telcyta is finito). Onyx is declining because it faces stiff competition from Pfizer's Sutent & now Wyeth's Torisol in renal cell carcinoma. Any sales increases for Onyx's Nexavar will come from off-label use in liver cancer, but that is not, in my opinion, a reason to invest. CEGE's recent decline is a gift - when European Revlimid sales appear on their balance sheet, along with clinical milestone press releases, it'll get back into the 60's. GNTA has been on a slippery slope for some time now - their CEO, Ray Warrell, is very smart, very committed, and held in high regard by his oncology peers at his alma mater, MSKCC. He is making use of FDA's dispute process for Genasense in CLL, so some investors are betting FDA will offer up a conditional approval in subsets of patients. The key here is that CLL is a very heterogeneous disease - therapy needs to be more individualized. Finally, in my opinion, ISRG is absolutely the future of surgery. Any decline into the low 130's is a bargain. Thanks again for your article! Reply
Loading...
Symbols:
Authors:
Quick Links: